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initiated at that time because the patient was reluctant to start
this treatment in the event that she became pregnant.
When the patient was evaluated in our office at the age of
21, we did not elicit a family history of renal disease. Her social
history was negative for tobacco, alcohol, and recreational drug
use. Her medications included insulin, 10–15 units of NPH and
20–25 units of regular insulin in the morning and 8 units of
NPH insulin and 10–15 units of regular insulin before dinner.
Her blood pressure was 121/68 mm Hg in the seated position
and 120/68 mm Hg in the standing position. Her heart rate
was 70 beats/min and 75 beats/min in the seated and standing
positions, respectively. Her fundi showed mild proliferative
changes. No hemorrhages were seen. Her abdomen was soft,
and no masses were felt. Her pulses in the lower extremities
were 2 bilaterally.
At that time the BUN and serum creatinine were 15 mg/dLCASE PRESENTATION
and 1.1 mg/dL, respectively. Her blood glucose was 160 mg/dLA 21-year-old white woman was referred for evaluation of
and HbA1c was 9.9%. Her serum electrolytes were: sodium,microalbuminuria. She stated that at the age of 11 a diagnosis
138 mmol/L; potassium, 4.1 mmol/L; calcium, 8.5 mg/dL (2.2of diabetes was made because of polyuria and polydipsia, and
mmol/L); and chloride, 103 mmol/L. Total cholesterol was 190she was begun on a regimen of insulin. Two months later,
mg/dL; fasting triglycerides, 140 mg/dL. Dipstick urinalysis wasshe was hospitalized with an episode of diabetic ketoacidosis.
negative for protein; a 24-hour urine collection indicated aReview of her medical records revealed no further episodes of
glomerular filtration rate (GFR) (creatinine clearance) of 115ketoacidosis. During her adolescence, compliance with insulin
mL/min, and an albumin excretion rate of 250 mg/24 hourstherapy was problematic despite frequent counseling and ad-
(Fig. 1).justment of her insulin dose. On one evaluation at the age of 18,
A 24-hour ambulatory blood pressure monitoring was doneher blood glucose was 200 mg/dL, and her plasma electrolytes,
at this time (Fig. 2). Mean systolic and diastolic blood pressuresblood urea nitrogen (BUN), and serum creatinine were in the
were 122 mm Hg and 70 mm Hg, respectively. Mean systolicnormal range. Her blood pressure while seated was 122/70
and diastolic blood pressures during the sleep period were 121mm Hg, and her heart rate was 86 beats/min. A urinalysis was
mm Hg and 69 mm Hg, respectively. Mean systolic and diastolicnormal with a negative dipstick for protein; a 24-hour urine
blood pressures during daily activities were 123 mm Hg andcollection revealed a creatinine clearance of 125 mL/min, and a
71 mm Hg, respectively. At that time, renoprotective therapyurine albumin excretion (UAE) rate of 20 mg/24 hours (normal,
with an ACE inhibitor, captopril at a dose of 25 mg orally twice0–30 mg/24 hours) (Fig. 1).
daily, was initiated. She also was referred to the EndocrinologyOver the following years, her glycemic control was poor, as
revealed by glycosylated hemoglobin (HbA1c) ranging between Clinic to optimize her glycemic control.
9% and 11%. When she was 20 years old, her pediatrician
found that the urine albumin excretion had increased to 200
DISCUSSIONmg/24 hours and referred the patient to us for nephrologic
evaluation. Therapy with an angiotensin-converting enzyme Dr. Daniel Batlle (Chief, Division of Nephrology;
(ACE) inhibitor was considered by her pediatrician but not
and Professor of Medicine, Northwestern University Fein-
berg School of Medicine, Chicago, Illinois, USA): Dia-
betic nephropathy is a microvascular complication of bothThe Nephrology Forum is funded in part by grants from Amgen,
Incorporated; Merck & Co., Incorporated; Dialysis Clinic, Incorpo- type 1 and type 2 diabetes, which is associated with end-
rated; and Bristol-Myers Squibb Company. stage renal disease (ESRD) and premature death from
cardiovascular disease [1, 2]. The development of clinicalKey words: end-stage renal disease, microalbuminuria, NHE-1, Na/H
antiporter, nocturnal hypertension, cell cycle proteins, cellular markers. nephropathy is insidious, and macroalbuminuria [urinary
albumin excretion rate300 mg/24 hours], the hallmark 2003 by the International Society of Nephrology
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Fig. 1. Three values of urinary albumin ex-
cretion from the patient discussed today ().
The first value was obtained when the patient
was normoalbuminuric; the remaining two
were obtained years later when the patient
had developed microalbuminuria. The solid
line depicts the progression of albumin excre-
tion from normal to microalbuminuria and
then to overt proteinuria in type 1 diabetics
who ultimately will develop nephropathy.
Years: duration from the diagnosis of diabetes
at age 11 during the normoalbuminuric phase.
of the condition, is preceded by a phase of microalbumin- patients with nephropathy seem to have an increased
incidence of cardiovascular disease as compared withuria (UAE 30–300 mg/24 hours), which usually lasts 5
to 10 years. As albuminuria worsens and blood pressure parents of type 1 diabetic patients with normal albumin
excretion [10]. Albuminuria, cardiovascular disease, andincreases, there is a relentless decline in GFR and pro-
gression to ESRD [2]. Tight metabolic control can reduce hypertension might be linked by an inherited predisposi-
tion to insulin resistance. Patients with nephropathy arethe incidence of nephropathy [3], but hyperglycemia
alone is not sufficient for the development of nephropa- more insulin-resistant than are non-nephropathic pa-
tients [14]. Insulin resistance also has been noted in par-thy. This is apparent from the finding that nephropathy
develops in some patients with type 1 diabetes despite ents of type 1 diabetic patients with proteinuria [14].
These clinical markers of increased risk for diabeticgood glycemic control and that a substantial proportion
of patients with poor control escape diabetic nephropa- nephropathy are useful in themselves, but we also need
genetic markers to define people at risk for nephropathythy [4–10]. Overall, only about one-third of type 1 diabe-
tes patients develop nephropathy, and the risk of ne- when the diagnosis of diabetes is made. Identification at
an early age would not only allow for more intensivephropathy appears, at least in part, to be genetically
determined [4–11]. follow-up of such patients, but also would provide insight
for the design of therapeutic approaches based on the
Clinical markers particular genetic marker [11]. Genes encoding the vari-
ous components of the renin-angiotensin-aldosteroneStrong evidence for genetic factors in nephropathy
system seem logical candidates for a genetic marker ofcame from studies of families with type 1 diabetes [6–9].
In families with two or more siblings with type 1 diabetes, susceptibility to nephropathy and its associated cardio-
vascular disease. No significant genetic marker of dia-when one sibling has developed nephropathy, the other
has a fourfold risk of nephropathy compared with a sib- betic nephropathy has been conclusively identified among
the components of the renin-angiotensin system or otherling of a patient without nephropathy [4, 6]. In a larger
study [7], if the proband had nephropathy, the cumula- potential candidates such as the aldose reductase gene
and the apolipoprotein E gene [11]. Recent studies, how-tive risk of nephropathy to diabetic siblings was 71.5%,
and the risk fell to 25.4% when the proband did not ever, suggest that certain polymorphisms of the ACE
gene might identify type 1 diabetic patients in whomhave nephropathy [2]. A recent analysis of the Diabetes
Control and Complications Trial (DCCT) cohort has diabetic nephropathy progresses at a faster rate (DD
genotype) and those who are responsive to renoprotec-confirmed these findings [8].
Other factors have been suggested as determinants of tive intervention using ACE inhibitors. These findings
were discussed by Dr. Hans-Henrich Parving in a recentrisk for diabetic nephropathy, including a family history
of hypertension [5, 12]. Parents of patients with type 1 Forum [2], and I will not review them here.
A marker is not necessarily based on the genotypediabetes who develop nephropathy have higher arterial
blood pressures than do parents of patients who have no (that is, an alteration of DNA), but it can be based on
phenotypic features, clinical or biochemical, that predictnephropathy [13]. Moreover, parents of type 1 diabetic
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Fig. 2. Tracing of 24-hour ambulatory blood pressure in the patient being discussed taken at the age of 21 when she was microalbuminuric. (A )
Systolic and diastolic blood pressure. (B ) Heart rate. Blood pressure throughout the 24-hour period, including the sleep period (0–6 hours), was
essentially the same.
Table 1. Markers of diabetic nephropathy in type 1 diabetes
Clinical Cellular phenotypes Genetic markers (potential)
Microalbuminuria Increased erythrocyte Na/Li countertransport Angiotensin-converting enzyme
Family history of nephropathy Na/H antiporter overactivity Angiotensinogen
Family history of HTN and/or insulin resistance Altered cell growth Angiotensin II, type 1 receptor
Increased GFR Cell cycle regulatory proteins (decreased p16?) Aldolase reductase
Nocturnal HTN (non-dipping status) Apolipoprotein E
with reasonable sensitivity and specificity the susceptibil- a marker and a predictor of nephropathy. Later we will
look at the potential role of cellular markers of diabeticity to diabetic nephropathy before it becomes clinically
evident [15]. Table 1 lists markers of diabetic nephropa- nephropathy, such as overactivity of the Na/H antipor-
ter and phenotypic features of altered cell growth.thy classified as clinical, cellular, or genetic. In this classi-
fication, the term marker is used loosely, in that it implies When today’s patient with type 1 diabetes was evalu-
ated at the age of 21, she had developed microalbumin-a predictive value for the development of nephropathy.
In this context, the best available predictor of diabetic uria (Fig. 1). Her GFR, estimated by the creatinine clear-
ance, was in the normal range, as is usually the casenephropathy to date is microalbuminuria. By the time
it develops, however, many patients have already ad- in microalbuminuric patients with type 1 diabetes. Her
blood pressure was likewise in the normal range, whichvanced renal structural changes on renal biopsy [16–18].
This suggests that rather than being a predictor of dia- also is usual for type 1 diabetics with microalbuminuria
[19, 20]. This finding is in sharp contrast with patientsbetic nephropathy, microalbuminuria is a marker of es-
tablished nephropathy. As part of my discussion of the with type 2 diabetes, in whom blood pressure is always
elevated by the time microalbuminuria is documentedpatient presented here, I will try to distinguish between
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[21]. In fact, type 2 diabetics are usually overtly hyperten- years of disease duration) is increasingly low. With a
disease duration of less than 15 years, the rate of progres-sive (that is, systolic blood pressure 145 mm Hg) when
the diagnosis of diabetes is made. With this background sion from microalbuminuria to proteinuria over the next
5 to 10 years has been estimated to be as much as 45%in mind, I would like to address two main issues: the
likelihood of progression to overt proteinuria from micro- [25]. This risk is still below the risk of nephropathy (about
80%) estimated from earlier studies.albuminuria, and whether microalbuminuria could have
been predicted in this patient when she was first seen The impact of therapy with an ACE inhibitor and/or
improved glycemic control on progression from micro-years ago by her pediatrician.
Until recently, if we had asked whether the microalbu- albuminuria to proteinuria also needs to be considered.
The DCCT demonstrated a positive effect of improvedminuria would have progressed to overt proteinuria, the
answer would have been a resounding “yes.” That is, it glycemic control on preventing microalbuminuria, but
not on the progression from microalbuminuria to pro-was only a matter of time before she progressed from
microalbuminuria to overt proteinuria, as depicted in teinuria [3]. Therapy with ACE inhibitors, by contrast,
retards the progression from microalbuminuria to pro-the typical course of nephropathy in type 1 diabetics
(Fig. 1). Indeed, initial retrospective studies in type 1 teinuria (see [28] for review). As documented by a meta-
regression analysis, ACE inhibitors reduce the progres-diabetics reported in the 1980s that the risk for progres-
sion from microalbuminuria to proteinuria over a period sion from microalbuminuria to overt proteinuria by 62%
compared to placebo [28]. Importantly, the impact ofof 6 to 14 years was as high as 80% [22–24]. Such a high
predictive value led to the broad acceptance of microalbu- ACE inhibitors on preventing progression from micro-
albuminuria to overt nephropathy lasts for many yearsminuria as a predictor of diabetic nephropathy. This
view, however, is no longer acceptable. Caramori, Fio- and is associated with preservation of GFR [29].
Other predictors of progression from microalbumin-retto, and Mauer [25] have convincingly argued that micro-
albuminuria is likely a marker rather than a predictor uria to proteinuria that should be considered include a
family history of diabetes, an abnormal lipid profile, andof renal structural changes. This argument is based on
the finding that in some patients with microalbuminuria, smoking [2], none of which was present in our patient.
Based on the foregoing considerations, I conclude thatrenal lesions are already quite advanced [11–13]. I know
of no prospective data regarding rates of progression while our patient is clearly at risk for progressing to
overt nephropathy, her risk is less than 50%, far belowbased on results of renal biopsy. For individuals with
advanced renal lesions, microalbuminuria is not a pre- the 80% estimated from earlier studies. Indeed, persis-
tent microalbuminuria does not predict clinical protein-dictor, but simply a sign of established nephropathy. In
others with only mild lesions on renal biopsy, microalbu- uria with more than 50% accuracy [25]. Clearly we need
additional markers or predictors of diabetic nephropa-minuria might not be a predictor of nephropathy. On
the other hand, regardless of findings on renal biopsy, thy. Moreover, with appropriate therapy, which includes
optimization of glycemic control and the use of an ACEmicroalbuminuria would be a powerful predictor of ne-
phropathy if most patients were to progress to overt inhibitor or perhaps an angiotensin receptor antagonist,
the risk of progression to overt proteinuria in our patientproteinuria as initially reported. However, more recent
studies have clearly shown that the percentage of micro- could be further reduced. Both interventions seem in
order, and it is quite conceivable that they have an addi-albuminuric patients progressing to proteinuria over
more than 10 years is only 30% to 45% [25–27]. Of the tive or even a synergistic effect.
I will now address the second issue, namely, whetherremaining patients in these more recent studies, 30%
became normoalbuminuric, and the rest remained micro- we could have predicted that this patient was going to
develop microalbuminuria when she was normoalbumi-albuminuric [25]. It should be noted that interpretation
of the data should take into account disease duration, nuric. At present, there is no simple way to predict the
development of microalbuminuria among type 1 diabet-as most diabetic patients destined to develop proteinuria
will do so within 20 years. Duration of diabetes is often ics. Only about 25% to 30% of patients with type 1
diabetes develop overt nephropathy, so one could infershorter in subjects with microalbuminuria progressing to
proteinuria (17  8 years) than in those remaining with that, in general, the risk for developing microalbumin-
uria cannot be much higher than that. This assumes thatmicroalbuminuria (22  9 years, P  0.005) [25].
In today’s 21-year-old patient, diabetes was diagnosed the development of proteinuria (macroalbuminuria) is
always preceded by a microalbuminuric phase that isat the age of 11 and microalbuminuria at the age of 20.
Accordingly, it is too early to predict, based on the crite- always progressive, but this might not be the case. Fors-
blom et al [26] found that about 7% of normoalbumi-ria of microalbuminuria and disease duration, whether
she will progress to proteinuria. If she remains micro- nuric patients progressed to proteinuria and 14% to
microalbuminuria over 10 years of follow-up. Thus, pro-albuminuric for another 10 years, her risk for progression
to proteinuria from that point on (that is, after about 20 gression took place in 21% of the patients when one
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adds both groups. In a different study, Mathiesen et al
[29] found a somewhat lower progression rate of micro-
albuminuria (10%) over a mean observation also of 10
years. Based on this and the review of other studies, Cara-
mori, Fioretto, and Mauer [25] estimated that 5% of
normoalbuminuric patients with at least 7 years of type
1 diabetes will progress to proteinuria over the following
5 to 10 years, whereas 17% will progress from normo-
albuminuria to microalbuminuria. In a recent study, we
found that in adolescents and young adults with type 1
diabetes, progression from normoalbuminuria to micro-
albuminuria over a follow-up of approximately 5 years
occurred in 18% [30]. This finding concurs with data
from other studies [25], although the follow-up period
was shorter in our patients. Fig. 3. Kaplan-Meier curves showing the probability of microalbumin-
The following should be considered risk factors for uria according to daytime and nighttime systolic pressure. The probabil-
ity of microalbuminuria differed significantly between the two groupsmicroalbuminuria: family history of nephropathy, poor
(P  0.01 by the log-rank test; chi-square  6.217 with 1 df). The risk ofglycemic control, changes in UAE (even with the normal microalbuminuria was 70% lower in the subjects with a normal nocturnal
albuminuric range), and increased GFR. Since progres- pattern than in those with an abnormal nocturnal pattern. (Reprinted
from the New England Journal of Medicine 347:797–805, 2002).sion from normoalbuminuria to proteinuria presumes
passing through a microalbuminuric phase, it seems rea-
sonable to infer that family history of nephropathy, de-
fined by dipstick proteinuria, also should predict the sure is already higher than in type 1 diabetics without
development of microalbuminuria [29]. It also seems rea-
microalbuminuria or in age-matched control subjects [19,
sonable to assume that poor glycemic control is a main
34–40]. A previous cross-sectional study led us to suggestdeterminant of progression because strict glycemic con-
that in type 1 diabetics susceptible to nephropathy, antrol retarded the progression to microalbuminuria in the
elevation in nocturnal blood pressure could antedate theDCCT study [3]. Indeed, normoalbuminuric patients
development of microalbuminuria [19].who progress to microalbuminuria have significantly
We examined the question of which comes first, micro-higher levels of HbA1c than do those who do not progress albuminuria or a rise in blood pressure in patients with[3, 24, 27, 31]. There was some indication that today’s
type 1 diabetes, using ABPM [30]. In this study by Lurbepatient was likely to progress to microalbuminuria,
et al [30], we followed 75 healthy normoalbuminuric andnamely the high level of HbA1c. Her creatinine clearance
normotensive patients with type 1 diabetes prospectivelywas in the normal range when she was normoalbumi-
over 5 years. Ambulatory blood pressure monitoring wasnuric, and we do not know whether her GFR had been
used to assess blood pressure changes during the awakeelevated earlier. While an increased GFR has been pro-
and sleep periods at evaluation and approximately 2posed as an early marker of progression to microalbu-
years later while all subjects had remained normoalbumi-minuria, controversy remains as to whether it is a pre-
nuric. Of the 75 patients studied, 18% developed micro-dictor of microalbuminuria [24, 25, 27]. This patient had
albuminuria and were classified as progressors. In theno family history of diabetes with renal disease, which, as
remaining subjects, the UAE remained in the normalI mentioned, greatly increases the risk for nephropathy.
range after a follow-up of about 5 years, and these pa-Measurements of UAE in the high rate of normal should
tients were classified as non-progressors. At initial evalu-be considered a risk factor, especially if the level rises
ation, systolic and diastolic blood pressure, either at theover repeated measurements [32]. In our patient, we had
office or as assessed during the awake and sleep periods,only one data point on UAE in the middle of the normo-
did not differ significantly between progressors and non-albuminuric range (Fig. 1). Therefore we cannot utilize
progressors. After a mean follow-up of about 2 years,this as a predictor of progression to microalbuminuria.
while all subjects were still normoalbuminuric, sleep sys-Now let’s look at the value of the blood pressure pattern
tolic blood pressure increased only in progressors. Byas a predictor of nephropathy in type 1 diabetics. Today’s
contrast, in non-progressors, sleep systolic blood pres-patient had a striking “non-dipping status” (Fig. 2).
sure remained unchanged. The risk of progression toIn type 1 diabetes with incipient nephropathy, defined
microalbuminuria was further examined on the basis ofby the presence of microalbuminuria, hypertension is not
“dipper” versus “non-dipper” status, defined by the ratiousually present [33]. Nevertheless, studies using ambula-
of sleep/awake systolic blood pressure (Fig. 3). A 70.2%tory blood pressure monitoring (ABPM) have shown
that at the microalbuminuric stage, nocturnal blood pres- reduction of risk for developing microalbuminuria was
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observed in “dippers” as compared with “non-dippers.” tein [5, 46]. Several isoforms of NHE (NHE-1 to 8) that
vary in molecular mass, level and type of glycosylation,A ratio of less than 0.9 had a negative predictive value
for the development of microalbuminuria of 90%. From sensitivity to inhibitors, and cell or tissue distribution
have been identified [47]. NHE-1, the first Na/H anti-these findings, we can conclude that in type 1 diabetics
susceptible to developing microalbuminuria, an increase porter cloned, is a 110 kD integral plasma membrane
glycoprotein [47, 48]. NHE-1 activity is extremely sensi-in systolic blood pressure during the sleep period pre-
cedes the increase in UAE [30]. Moreover, microalbu- tive to intracellular pH (pHi) owing to the presence of
a proton activation site [49], and this pHi dependencyminuria is highly unlikely to develop in type 1 diabetics
in whom systolic blood pressure during sleep does not protects the cell against acute cytoplasmic acidification.
NHE-1 activity, in concert with other pHi regulatoryincrease over about 5 years. The finding of a “dipping”
pattern of systolic blood pressure has a strong negative plasma membrane proteins such as the Na-dependent
and Na-independent Cl/HCO3 , determines the pHipredictive value for progression to microalbuminuria
[30]. In other words, normal dipping is a strong predictor set point [50–52]. Erythrocyte Na/Li exchange activity
correlates with proximal tubular NHE-3 expression [53];of non-progression to microalbuminuria.
The patient discussed here today had a 24-hour ambu- thus it may be used as a marker of the NHE-3 isoform,
which is located in the apical border of the proximallatory blood pressure pattern characterized by a flat line
in both systolic and diastolic blood pressure (Fig. 2). In tubule and is involved with renal Na reabsorption.
In type 1 diabetic patients with nephropathy, an in-fact, this pattern is unusual because there is no trace of
“dipping” whatsoever during sleep; she thus is an ex- crease in the activity of the Na/H antiporter has been
reported in a variety of cell types: cultured skin fibro-treme case of non-dipping status reflecting nocturnal hy-
pertension. If this pattern had already been present when blasts [54–58], immortalized lymphoblasts [58–61], plate-
lets [62], and leukocytes [63]. We evaluated Na/H anti-she was normoalbuminuric, as in the subjects in the pro-
spective study that I just described, it could be inferred porter activity and its relationship to DNA and protein
synthesis in cultured skin fibroblasts from patients withthat she had a high risk for microalbuminuria. Stated
differently, her lack of a normal dipping status—a strong type 1 diabetes classified as having either overt nephrop-
athy or the absence of nephropathy on the basis of urinarynegative predictor of microalbuminuria—puts her at
high risk of progression. Moreover, we know from previ- albumin excretion and renal biopsy findings [54]. In type
1 diabetic patients with overt nephropathy (mean urinaryous cross-sectional studies that most microalbuminuric
patients with type 1 diabetes are non-dippers [19, 34–40]. albumin excretion, 979  292 g/min), Na/H antipor-
ter activity in serum-stimulated cells was increased asIn our initial cross-sectional study, 9 of 11 microalbumi-
nuric patients (82%) had an abnormal night-day ratio compared to cells from control subjects and cells from
patients without nephropathy (UAE, 6.7  7.9 g/min).consistent with a non-dipping status [19]. Altogether, the
lack of “dipping” is a sign of progression to microalbu- By contrast, in cells made quiescent by serum depriva-
tion, we found no significant differences in Na/H ex-minuria, and the mere presence of microalbuminuria
suggests a non-dipping status. Since a non-dipping status change activity among the three groups [54]. Intracellular
pH in serum-stimulated fibroblasts from patients withprecedes the development of microalbuminuria, it fol-
lows that non-dipping might be an earlier and thus a type 1 diabetes and nephropathy was higher than that of
patients without nephropathy (7.34  0.04 and 7.24 more sensitive predictor of nephropathy. Also, rapid
progression from microalbuminuria to overt nephropa- 0.03, respectively), but this difference did not achieve
statistical significance [54].thy was described in a small group of “non-dippers” [41].
A blunted nocturnal decline in arterial blood pressure Several other studies have used the skin fibroblast
model to study Na/H antiporter activity in diabeticsis also seen in type 2 diabetes with nephropathy [42] and
is increasingly recognized as a risk factor for cardiovascu- with and without nephropathy [55–58]. All these studies
have consistently reported increased activity in cells fromlar disease in diabetic and non-diabetic subjects [43, 44].
Non-dipping therefore can be viewed as both a predictor diabetics with nephropathy [54–58]. An important fea-
ture in all these studies is that blood pressure was higherof microalbuminuria and a marker of progression to ne-
phropathy and its associated cardiovascular complications. in diabetics with nephropathy than in those without ne-
phropathy (or was similar, but the diabetics with nephrop-
Cellular markers athy were hypertensives treated with antihypertensive
medications). Thus, hypertension cannot be excluded asA list of possible cellular markers of nephropathy is
given in Table 1. Na/Li exchange activity [5, 45] and the link between the Na/H antiporter overactivity and
nephropathy in type 1 diabetics.Na/H (NHE) exchange activity [46] are both increased
in type 1 diabetics with nephropathy. In fact, Na/Li ex- Our group and others found a difference in Na/H
antiporter activity in studies in which HbA1c was higherchange might represent a functional mode of the plasma
membrane Na/H exchanger or a closely related pro- in diabetics with nephropathy but also in others in which
Nephrology Forum: Markers of diabetic nephropathy 2325
differences in this parameter were not apparent [54–58].
That the difference in Na/H antiporter activity cannot
be explained by differences in metabolic control is fur-
ther suggested by the findings that, in vitro, such differ-
ence in activity has been reported in studies in which the
glucose concentration was high (17.9 mmol/L) [54–57] or
normal (5 mmol/L) [58]. In fact, one of the great advan-
tages of the in vitro model is that the external environment
can be controlled at will, including the glucose concentra-
tion and the presence of insulin and other hormones in
the media. Familial concordance for Na/H antiporter
activity in long-term cultured skin fibroblasts from type
1 diabetic siblings suggests that at least some of the in
Fig. 4. Thymidine incorporation in cultured skin fibroblasts from threevitro phenotypic characteristics of these cells are likely
groups of patients—controls, type 1 diabetics without nephropathy, andto be genetically determined and, at least in part, inde- those with nephropathy—in the absence and presence of ethyl-isopro-
pendent of in vivo metabolic control [64]. The fact that pyl-amiloride (EIPA). [3H] thymdine incorporation was significantly
increased in cells from diabetic patients with nephropathy as compareddifferences in Na/H antiporter activity were seen only
to controls, whereas cells from diabetic subjects without nephropathyin serum-stimulated fibroblasts suggested to us that these had an intermediate level. The percent reduction of [3H] thymidine by
differences were related to cell growth. To address this EIPA was similar in all three groups, so that the difference persisted.
(Figure modified from data published in Kidney International 50:1684–issue, our studies also measured DNA synthesis and cell
1693, 1996).size concurrently with Na/H antiporter activity. The
activity of the Na/H antiporter (NHE-1) has long been
suspected of playing a role in cell growth.
Pharmacologic NHE-1 inhibitors block vascular smooth fibroblasts from type 1 diabetics with nephropathy display
an abnormal growth phenotype characterized by cell hy-muscle cell (VSMC) proliferation in vitro [65] and in
vivo [66]. Moreover, overexpression of NHE-1 increased perplasia but not hypertrophy and that this phenotype
is associated with overactivity of the Na/H antiporterproliferation of VSMC [67], and specific mitogens have
an effect on the NHE-1 promoter [67, 68]. Glucose is during stimulation of cell growth by serum [54]. Our
study was unique in that the type 1 diabetics withoutalso thought to act through protein kinase C (PKC) to
increase message levels in certain cell types [69]. During microalbuminuria were selected on the basis of long dis-
ease duration and nearly normal mesangial cell structurecell proliferation, NHE-1 is responsible for an elevation
of pHi, which seems to play a permissive role in the by morphometric analysis [54]. Therefore the risk of
progression to nephropathy under these conditions shouldgrowth of some cell types. Also, actively proliferating
tumor cells often are more alkaline than are normal cells, be very low. The findings of intermediate values of both
Na/H antiporter activity and DNA synthesis in fibro-and inhibitors of the exchanger help reduce their rate
of proliferation. It remains to be proven, however, that blasts from such patients, as compared to those from
normal subjects and type 1 diabetics with overt nephrop-this activation is essential for the cells to progress through
the cell cycle. athy, might reflect either an effect of diabetes per se
(hyperglycemia) or attenuated phenotypic features re-Earlier studies using skin fibroblasts from patients with
type 1 diabetes showed a decreased replicative lifespan, flecting individuals less likely to progress in terms of
nephropathy and/or microvascular complications.consistent with premature senescence, although other
studies have not confirmed this finding [70–72]. An in- If overactivity of the antiporter were the primary rea-
son for increased DNA synthesis, then its inhibitioncreased proliferation rate and increased DNA synthesis
in type 1 diabetics with nephropathy have been found in should obliterate any differences in cell growth between
diabetics with and without nephropathy. A pharmaco-studies by Viberti and his associates [55, 56]. Interestingly,
some of these phenotypic features have been reported logic approach consisting of pre-incubating cultured skin
fibroblasts with a relatively specific inhibitor of the anti-in cells from hypertensive patients as well [73]. In our
study, DNA synthesis, assessed by [3H] thymidine incor- porter, ethyl-isopropyl-amiloride (EIPA), was used to
test this hypothesis [54]. After chronic inhibition of theporation, was increased in a group of type 1 diabetics
with nephropathy as compared to a group without ne- Na/H antiporter using EIPA (25 mol/L), [3H] thymi-
dine incorporation was reduced by about 20% in cellsphropathy and to control subjects (Fig. 4). By contrast,
protein synthesis assessed by [14C] L-leucine incorpora- from diabetic patients and from controls. [3H] thymidine
incorporation therefore remained higher in cells fromtion was not increased in fibroblasts from type 1 diabetics
with nephropathy; this finding suggested a lack of cellular type 1 diabetics with nephropathy than in those from
controls, whereas cells from type 1 diabetics withouthypertrophy [54]. We thus concluded that cultured skin
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nephropathy displayed intermediate values (Fig. 4). We is a predictor of nephropathy or simply an alteration
concluded that Na/H exchange activity is required for associated with nephropathy.
optimal cell growth, but that in itself it cannot account Finally, hyperglycemia itself increases VSMC Na/H
for differences in DNA synthesis in diabetics with ne- exchange activity and growth [69]. It is not completely
phropathy as compared to those without nephropathy possible to separate the effect of metabolic control in
and to controls [54]. vivo from its long-term effect in vitro, even after several
Further insight into the risk of nephropathy might passages in culture. Genes might be turned on in vivo
come from studies at the cellular level focusing on alter- during poor hyperglycemic control that could remain
ations in cell-cycle regulatory proteins, which control the overexpressed after several passages in culture. The issue
rate of DNA synthesis. Such alterations could explain of hyperglycemic memory is unraveling quickly, particu-
the abnormal growth phenotype of diabetics, particularly larly because its long-term effect in vivo is becoming
those with nephropathy. Progression through the G1 evident [78, 79]. For instance, the effects of intensive
phase of the cell cycle is not only controlled by positive versus conventional insulin therapy on the occurrence
regulators, the G1 cyclins, but is also under negative and severity of post-study retinopathy and nephropathy
control of a number of different cyclin-dependent kinase were shown to persist for 4 years after the DCCT, despite
inhibitor proteins (CDK1). My laboratory has been ex-
nearly identical glycosylated hemoglobin values during
amining the hypothesis that cultured skin fibroblasts
the 4-year follow-up [79]. Hence, the so-called phenome-from diabetics with nephropathy have a hyperplastic
non of hyperglycemic memory, which refers to the occur-growth phenotype either because of overexpression of
rence of persistent renal damage during subsequent peri-one or several of the cell cycle positive regulators, or
ods of normal glucose control. This phenomenon mightunderexpression of one or more of the negative regula-
translate into phenotypic features in vitro and partlytors [74, 75]. One of the negative cell cycle regulatory
explain why alterations in cell growth and Na/H anti-proteins, p16, a member of the INK4 family, inhibits the
porter activity observed in cultured skin fibroblasts arekinase activity associated with CDK4 and CDK6 without
usually described in patients with poor metabolic control.affecting other CDKs and appears to act by blocking the
association of CDK4,6 with D-type cyclins, thus pre-
venting the activation of the kinases [76, 77]. We have
CONCLUSIONshown that the levels of p16 protein are suppressed in
Prospective studies are needed to establish the pre-skin fibroblasts from type 1 diabetics with overt nephrop-
athy as compared to those without nephropathy (ab- dictive value of clinical and cellular markers for early
stract; Danesh et al, J Am Soc Nephrol 11:638A, 2000); identification of diabetic patients at risk for the develop-
this finding suggests the possibility that low levels of p16 ment of nephropathy. Such patients at risk could benefit
are a marker for nephropathy in type 1 diabetics. from early intervention, such as the use of ACE inhibi-
As I said, most type 1 diabetics with nephropathy tors or angiotensin II blockers, which might not be
involved in studies of Na/H antiporter activity were needed in patients at reduced risk for nephropathy. The
hypertensive. Importantly, an increased turnover number best clinical marker available to date, microalbuminuria,
of NHE-1 also has been noted in immortalized lympho- predicts clinical nephropathy to a lesser extent than origi-
blasts from hypertensive subjects [73]. It is therefore pos- nally described. Thus, the need exists for additional
sible that the NHE-1 alteration reflects a hypertensive markers that either alone or in combination with micro-
rather than a diabetic phenotype. Additional studies us- albuminuria will identify early the individuals susceptible
ing patients with diabetic nephropathy who have not to clinical nephropathy. We have suggested that a “non-
developed hypertension would be critically important to
dipping” status in type 1 diabetics without either micro-
see whether a diabetic “nephropathic” phenotype exists
albuminuria or hypertension predicts the developmentindependently of hypertension. Cells from nondiabetic
of microalbuminuria [30]. Further studies are needed tohypertensive subjects should be used as controls to fur-
see whether it also predicts the development of clinicalther elucidate whether the phenotype is “hypertensive”
nephropathy. This clinical marker, used in conjunctionor “nephropathic.” Ideally, diabetic patients who have
with other known risk factors, such as high level of HbA1cnot yet developed hypertension, not even nocturnal hy-
and family history of nephropathy, translates into a pro-pertension, should be followed longitudinally until the
file of high risk for diabetic nephropathy. Potential cellu-development of microalbuminuria. Such studies also
lar markers such as overactivity of the Na/H antiporterwould be the first to examine whether overactivity of
(NHE-1 isoform) and phenotypic changes in cell growthNHE-1 has a predictive value for the development of
and cell cycle proteins expressed in vitro by cells ofnephropathy. To my knowledge, all studies to date have
diabetics with nephropathy are also worthy of furtherbeen cross-sectional and therefore have not established
whether the overactive Na/H antiporter phenotype study.
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QUESTIONS AND ANSWERS Dr. Batlle: We made this observation in type 1 dia-
betics with overt nephropathy [54]. There are no studiesDr. John T. Harrington (Dean, Tufts University
showing that this alteration is already present prior to theSchool of Medicine, Boston, Massachusetts): Do we know
development of nephropathy. Accordingly, we cannotwhat factors are the root cause of the “non-dipping”
claim that it has a predictive value at this time. Perhapsphenomenon? If so, can we block some of those factors?
certain cell cycle regulatory proteins are abnormally ex-Dr. Batlle: This question can be addressed by consid-
pressed or regulated in patients with nephropathy andering the normal regulation of nocturnal blood pressure.
this is the cause of this abnormal growth pattern.During sleep the blood pressure falls as a result of a
Dr. Andrew S. Levey (Division of Nephrology, Tufts-decrease in both cardiac output and peripheral resistance.
New England Medical Center, Boston, Massachusetts):This physiologic fall in cardiac output is associated with
Let me ask about the cyclin-dependent kinase inhibitor,a decrease in heart rate, an increase in vagal tone, and
p16, which you showed to be abnormal. Is this a genetica decrease in sympathetic tone. By extrapolation, it is
factor? Is this a susceptibility factor? Are the peoplereasonable to postulate that diabetics in whom blood pres-
more prone to increased cell growth the ones who de-sure does not fall normally during sleep have an overactive
velop nephropathy, or is this a consequence of havingsympathetic system, which is consistent with the auto-
diabetes?nomic dysfunction that is so prevalent in diabetics.
Dr. Batlle: The hyperplastic phenotype observed inDr. Harrington: Do we have evidence for that, or is
cultured skin fibroblasts from patients with type 1 diabe-it speculation?
tes seems to be limited to those who have establishedDr. Batlle: Studies suggest that autonomic dysfunc-
nephropathy [54]. Our working hypothesis has been thattion is prevalent in diabetics who are “non-dippers”
a high level of cyclin D1 or a low level of a cyclin-[40, 80]. In type 1 diabetics with intermittent microalbu-
dependent kinase inhibitor, such as p16, could be aminuria, early signs of subclinical autonomic neuropathy,
marker of susceptibility to nephropathy and not the con-such as reduced papillary reaction to darkness, are al-
sequence of diabetes per se [74]. I know of no dataready present [81]. We have shown that most microal-
showing that diabetes (that is, a hyperglycemic environ-buminuric patients with type 1 diabetes have an abnor-
ment) regulates the p16 gene. We know that the p16mal nocturnal blood pressure pattern [19]. It seems safe
gene is involved in the regulation of cell growth by re-to extrapolate that autonomic dysfunction is usually
tarding G1 transition and entry into the S phase of thepresent during the microalbuminuric phase of diabetic
cell cycle. It makes sense that a low level of an inhibitornephropathy. Type 2 diabetics also manifest evidence of
of cell cycle progression would facilitate progressionautonomic dysfunction. Moreover, in type 2 diabetics
through G1 phase and potentially lead to increased cellwith nephropathy, the “non-dipping” phenomenon has
replication and exaggerated cell growth [76, 77].been associated with orthostatic hypotension [80]. Thus,
Dr. Levey: I would like to challenge the notion thatin both type 1 and type 2 diabetics, autonomic dysfunc-
microalbuminuria predicts the development of diseasetion, non-dipping, and nephropathy often co-exist and
as opposed to being a marker for the presence of disease.might be intimately related. That is not to say, however,
Would you at least acknowledge that the relatively shortthat autonomic dysfunction is the sole explanation for
follow-up in some studies, 10 years, might be related tothe “non-dipping” phenomenon often seen in diabetics
the lower incidence of clinical nephropathy? It mightwith nephropathy.
be that another 5 to 10 years of follow-up would haveDr. Harrington: What diseases other than diabetes
demonstrated the development of clinical proteinuria,also have a “non-dipping” phenomenon?
thereby improving the predictive value of microalbumin-Dr. Batlle: The “non-dipping” phenomenon was first
uria.described, to my knowledge, in subjects with secondary
Dr. Batlle: Your question really brings in the pointcauses of hypertension. “Non-dipping” is also more prev-
of why the more recent studies have shown a much loweralent in certain populations with essential hypertension
rate of transition of microalbuminuria to overt protein-such as African-Americans. I believe the percentage of
uria than the initial ones. The excellent review by Cara-“non-dippers” in African-Americans with hypertension
mori, Fioreto, and Mauer [25] could not find a singleis close to 30%. So, it is not a unique phenomenon of
explanation for this. Maybe the natural history of thetype 1 diabetics but, in the context of an individual with
disease has changed, and it seems clear that glycemicdiabetes who is not yet hypertensive in the office, “non-
control has improved over the last decade. I cannot saydipping” should be viewed as a potential index of pro-
that the disease duration was a main factor. In the reviewgression to microalbuminuria.
by Caramori, Fioreto, and Mauer, only data that metDr. Harrington: You showed increased thymidine in-
the criterion of an interval of about 10 years of knowncorporation in cells from diabetic patients who are likely
diabetes (disease duration) were included for analysisto progress to nephropathy. What is the cause of this
phenomenon? [25]. So disease duration was taken into consideration
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already. Despite similar disease duration, the conversion not always taken into account has led to conflicting re-
sults. Another limitation probably comes from the diffi-rate to overt proteinuria seems to be much lower than
originally stated. Having said that, I agree that in some culty in measuring GFR accurately and frequently. Even
the better methods of measuring GFR have been difficultpatients conversion from microalbuminuria to protein-
uria takes place after more than 10 years of microalbu- to standardize. I am fond of the MDRD formula that
Dr. Levey has popularized. I believe this formula is goodminuria. After more than 20 years of diabetes, however,
the development of nephropathy is very unlikely. for estimating the GFR, and it allows us to have frequent
and serial values of GFR.Dr. Bertrand L. Jaber (Division of Nephrology, Tufts-
New England Medical Center): Since the absence of noc- Dr. Levey: I had the opportunity to review renal func-
tion data from the DCCT, in which GFR was measuredturnal blood pressure “dipping” is associated with pro-
gression of diabetic nephropathy, do ACE inhibitors in a large subgroup of patients from the beginning of the
study. Creatinine clearance was measured in all patients,re-establish nocturnal blood pressure “dipping” patterns?
Such an effect could account for some of the beneficial and baseline GFR was measured in a large subgroup of
the patients. We found no association between hyperfil-properties of this class of medications.
Dr. Batlle: I am not aware of any studies on this tration and subsequent development of microalbumin-
uria in that study. Hyperfiltration was not a predictor,area but it is something we are studying now. In general,
most antihypertensives lower the blood pressure through- nor did it interact with the treatment effect of intensive
glycemic control.out a 24-hour period. Some clinical trials of antihyperten-
sive drugs, including those using ACE inhibitors, have Dr. Harrington: Do you think the prediction equa-
tion would be the standard equation for GFR in thisprovided us with 24-hour ambulatory blood pressure
data before and after treatment. Usually, blood pressure early stage of nephropathy?
Dr. Levey: I would have some reservations about us-falls throughout the day and night during treatment, and
striking effects limited to the nocturnal pattern have not ing GFR prediction equations in this early stage of ne-
phropathy because they have not been shown to be accu-been reported. Whether ACE inhibitors have a special
effect on nocturnal hypertension needs to be investi- rate in individuals with very low serum creatinine levels.
gated. My collaborators in Spain have observed near The problem is using non-systemic calibration of creati-
normalization of nocturnal hypertension in a few mi- nine assays to account for errors due to interference
croalbuminuric patients treated with captopril (Lurbe by non-creatinine chromogens. In patients with serum
et al, unpublished data). There might be interactions creatinine below 1.0 mg/dL, systemic differences in cali-
between the renin-angiotensin and sympathetic nervous bration among laboratories could lead to large errors in
systems that ACE inhibitors affect, returning to normal estimated GFR. The formulae were very accurate in the
the abnormal nocturnal blood pressure pattern. MDRD study in patients with GFR as high as 90 mL/min/
Dr. Harrington: How would you incorporate those 1.73 m2 and in the African-American Study of Kidney
observations on the “non-dipping” phenomenon with Disease and Hypertension (AASK) with GFRs up to
what we know about the adverse prognostic effect of 100 to 110 mL/min/1.73 m2. However, young patients
having the “DD” ACE alleles? with diabetes can have GFRs140 mL/min/1.73 m2 with
Dr. Batlle: Only by way of a possible association. serum creatinine levels below 1.0 mg/dL.
What has been suggested so far is that diabetics with the
Reprint requests to Dr. D. Batlle, Chief, Division of Nephrology,DD genotype of the ACE gene have an accelerated Northwestern University Feinberg School of Medicine, 303 East Chicago
progression to ESRD [82]. I also can cite a study showing Avenue, Chicago, IL 60611-3008, USA.
E-mail: d-batlle@northwestern.eduthat proteinuric patients with a “non-dipping” status also
progress at a faster rate [37]. Perhaps those individuals
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